HLB제약

047920KOSDAQ자연과학 및 공학 연구개발업

57.3 / 100

Reference Date: 2026-07-24

Financial Score21.5 / 40

News Sentiment18.8 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 33.9% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Pharmaceuticals, established in 1998, focuses on specialty pharmaceutical manufacturing, CMO services, and health functional food sales. In 2025, it expanded into pharmaceutical distribution by acquiring 100% of Shinwha Advance, achieving a 2025 revenue of 2.055 trillion KRW with a 34% CAGR over five years. The company leverages its DDS technology for long-acting injectables and diversified growth through its joint health functional food brand 'Kwancheol'.

Number of Employees

185people

Average Salary

54.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

57.23Industry Average 43.643.0Point

Higher than industry avg (caution)

PBR

2.12Industry Average 2.524.0Point

In line with industry avg

ROE

3.79Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

4.72Industry Average 7.315.0Point

Lower than industry avg (good)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲25.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲39.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -5.5% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 1Neutral 0Negative 2Average Sentiment Score 75

Positive
[애프터마켓 리뷰] 로킷헬스케어, 신장재생 임상 수술 전 세계 첫 도전
HLB제약 관련 직접적 영향은 없으나, 로킷헬스케어의 신장재생술 임상 성공 소식이 긍정적 영향을 미쳐 HLB제약에 간접적으로 긍정적인 시장 분위기를 조성.
Negative
HLB 간암신약 결국 세 번째 CRL…허가 지연에 상업성 우려까지
HLB제약의 간암 신약 임상 시험이 FDA로부터 세 번째 보완요구서한을 받으며 상업화 지연 우려가 제기되었다.
Negative
[ET특징주] HLB, 간암 신약 후보물질 FDA 허가 불발… 그룹주 ...
HLB제약의 간암 신약 후보물질 FDA 허가 거부로 인해 주가가 급락했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 8,070Won52-week high 20,90052-week low 6,170

1-month return0.0Point

1m -33.85% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-22
Neutral주식등의대량보유상황보고서(일반)2026-07-16
Neutral효력발생안내( 2026.6.18. 제출 증권신고서(지분증권) )2026-07-03
Neutral투자설명서2026-07-03
Neutral[기재정정]증권신고서(지분증권)2026-07-02